New Study on OTC Progesterone Health Risks in Women Published
Posted on: Wednesday, 13 July 2005, 14:50 CDT
Thousand Oaks, CA, USA (July 13, 2005) – There has been considerable concern about the risk that many over-the counter (OTC) cosmetic preparations may pose to the public, since many of these are not regulated by the FDA and are commonly used without medical supervision. Progesterone, which is commonly prescribed in women, is often used in hormone replacement therapy in postmenopausal women, and for the treatment of amenorrhea, infertility and premature labor. Past studies revealing the health risks of FDA–approved hormone replacement therapy (including oral progesterones and progestins) have contributed to dramatic declines in prescriptions for these products. However, unregulated natural progesterone continues to be sold over-the-counter in the form of herbal beauty creams, thus exempting them from regulatory scrutiny.
In a study recently published in The Journal of Clinical Pharmacology, (June 2005) researchers found substantial evidence that use of OTC topical progesterone results in similar drug exposure through skin absorption as that which results from taking a prescribed oral progesterone product.
The Bassett Healthcare supported study, led by Drs. Anne C. Hermann, Anne Nafziger and Joseph Bertino, consisted of twelve, healthy, post-menopausal women. Each subject was treated with topical OTC progesterone (Pro-gest cream) in one phase and prescribed oral progesterone (Prometrium) in the other phase of the study. According to the results, there was no difference between the two groups in the amount of progesterone exposure in the body. The women involved in this study also experienced similar rates of adverse effects while taking each type of progesterone. This study differed from previous studies because of its use of more precise and advanced drug analysis methods, giving results that are accurate compared to previous studies with topical progesterone products.
Given the risks associated with prolonged progesterone therapy, the researchers note with concern that women may be exposing themselves to similar risks without the counseling, screening and supervision that accompany the use of prescription products.
On the Internet:
Related Articles
- Agnico-Eagle reports Q2 2009 results; Record quarterly gold production
- Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
- XBRL US Pacific Rim Technology Workshop to Feature Case Studies and Advanced Topics in XML Development, Santa Clara, CA, 7/28-30, 2009
- Agnico-Eagle reports Q1 2009 results; Record quarterly gold production; Lapa Mine produces first gold; Kittila mill commissioning ongoing
- ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
- CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (Atazanavir Sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
- Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
- Anacor Phase 2 Study of Novel Topical Antifungal for Onychomycosis Demonstrates Efficacy
- Wyeth Seeks Approval for Women's Health Therapies
- Study: Product Innovation Lags for Elders
 |
 |
User Comments (0)
RSS Feeds